Blood-Based Proteomic Biomarkers of Alzheimer's Disease Pathology.

ABSTRACT: The complexity of Alzheimer's disease (AD) and its long prodromal phase poses challenges for early diagnosis and yet allows for the possibility of the development of disease modifying treatments for secondary prevention. It is, therefore, of importance to develop biomarkers, in particular, in the preclinical or early phases that reflect the pathological characteristics of the disease and, moreover, could be of utility in triaging subjects for preventative therapeutic clinical trials. Much research has sought biomarkers for diagnostic purposes by comparing affected people to unaffected controls. However, given that AD pathology precedes disease onset, a pathology endophenotype design for biomarker discovery creates the opportunity for detection of much earlier markers of disease. Blood-base

SUBMITTER: Baird AL 

PROVIDER: S-EPMC4644785 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature